■脂肪肉瘤是一种恶性肿瘤,起源于脂肪组织,可发生在身体的任何部位。目前对于不同解剖位置的脂肪肉瘤之间的预后是否存在显著差异尚无明确的结论。特别是腹膜后脂肪肉瘤(RLPS)和非腹膜后脂肪肉瘤(NRLPS)。这项研究的目的是揭示这两个位置的脂肪肉瘤之间的预后是否存在差异,并进一步探讨这些差异背后的根本原因。
■我们通过分析来自监测的数据,对影响脂肪肉瘤患者预后的因素进行了深入调查,流行病学,和最终结果计划(SEER)数据库。然后,我们使用倾向评分匹配(PSM)来平衡这些预后因素,以比较RLPS和NRLPS之间的生存率.此外,通过分析TCGA和日本基因型表型档案(JGA)的转录组和全外显子组数据,我们鉴定了具有显著表达差异的基因,并探索了免疫微环境的变化。
■通过对SEER数据库中RLPS和NRLPS患者的分析,我们观察到两组之间的显着预后差异,RLPS的预后较差(p<0.001)。即使在通过PSM调整了混杂因素之后,这些生存率差异仍然很大,RLPS仍显示较差的预后(p=0.017)。此外,我们对转录组数据的分析导致了467个差异表达基因的鉴定.此外,我们注意到两组之间在免疫微环境和整个外显子组测序数据方面存在显著差异.
■RLPS和NRLPS患者之间存在显着差异。因此,从临床研究到治疗策略,RLPS和NRLPS应被视为两种不同类型的肿瘤,他们的研究和治疗需要差异化的方法。
UNASSIGNED: Liposarcoma is a malignant tumor that originates from adipose tissue and can occur in any part of the body. There is currently no clear conclusion on whether there are significant differences in prognosis between
liposarcoma at different anatomical locations, especially retroperitoneal
liposarcoma (RLPS) and non retroperitoneal
liposarcoma (NRLPS). The aim of this study is to reveal whether there are differences in prognosis between these two locations of
liposarcoma, and further explore the fundamental reasons behind these differences.
UNASSIGNED: We conducted an in-depth investigation into the factors affecting the prognosis of patients with liposarcoma by analyzing the data from the Surveillance, Epidemiology, and End Results Program (SEER) database. Then, we used propensity score matching (PSM) to balance these prognostic factors for comparative analysis of survival between RLPS and NRLPS. In addition, by analyzing transcriptome and whole exome data from TCGA and the Japan Genotypic Phenotype Archive (JGA), we identified genes with significant expression differences and explored changes in the immune microenvironment.
UNASSIGNED: Through analysis of RLPS and NRLPS patients in the SEER database, we observed significant prognostic differences between the two groups, with RLPS exhibiting worse prognosis (p < 0.001). Even after adjusting for confounding factors through PSM, these survival rate differences remained significant, with RLPS still showing worse prognosis (p = 0.017). Furthermore, our analysis of transcriptomic data led to the identification of 467 differentially expressed genes. Additionally, we noted significant differences in the immune microenvironment and whole exome sequencing data between the two groups.
UNASSIGNED: There are significant differences between patients with RLPS and NRLPS. Therefore, from clinical research to treatment strategies, RLPS and NRLPS should be considered as two distinct types of tumors, necessitating differentiated approaches for their study and treatment.